Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could of ...
The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...
Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...
Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback